Bicycle Therapeutics plc — Earnings
Most recent reported period: FY2026 (Q1) (filed for period ending 2026-03-31) · sourced from SEC EDGAR
Next earnings (estimated): Tue, June 30, 2026 — ~60 days away. Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2026-03-31 | $887K | ↓-91.1% | $-61M | ↓-0.1% | -7382.4% |
| 2025-12-31 | $48M | ↑+1193.3% | — | — | — |
| 2025-09-30 | $12M | ↑+338.5% | $-59M | ↓-16.3% | -558.6% |
| 2025-06-30 | $3M | ↓-68.8% | $-79M | ↓-98.3% | -2965.8% |
| 2025-03-31 | $10M | ↓-48.9% | $-61M | ↓-128.7% | -703.7% |
| 2024-12-31 | $4M | ↓-30.4% | — | — | — |
| 2024-09-30 | $3M | ↓-50.0% | $-51M | ↓-1.8% | -2385.9% |
| 2024-06-30 | $9M | ↓-17.9% | $-40M | ↑+6.6% | -498.3% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2026 (Q1)
Revenue
$887K
↓-91.1% -$9M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
BCYC Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyBCYC Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics